Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

Abstract Background Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood–brain barrier (BBB) penetration is highly desirable. Methods The design and structure–activity...

Full description

Bibliographic Details
Main Authors: Jian Zhang, Nicholas P. McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo, Mei Wang, Kan Chen, Wenlei Yu, Xichun Hu
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Breast Cancer Research
Subjects:
HER2
Tyrosine kinase inhibitor
Blood–brain barrier
Breast cancer
Central nervous system metastases
Online Access:https://doi.org/10.1186/s13058-023-01679-4

Internet

https://doi.org/10.1186/s13058-023-01679-4

Similar Items